A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder

Lee, Rico S.C.; Hermens, Daniel F.; Porter, Melanie; Redoblado-Hodge, Marie Antoinette

doi:10.1016/j.jad.2011.10.023

Cited by 614 publications

(483 citation statements)

References 75 publications

Supporting

Mentioning

420

Contrasting

Unclassified

Order By: Relevance

“…domain. [23][24][25] In the FOCUS study, 9 the standardized effect sizes for the DSST were 0.56 (10 mg) and 0.61 (20 mg) in the working MDD population compared to 0.48 (10 and 20 mg) in total study population. Hence, the magnitude of improvement in the DSST in working patients with MDD with vortioxetine treatment compared to placebo is as large as the baseline deficits found in individuals with MDD versus the normative population.…”

Section: Discussionmentioning

confidence: 95%

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre¹,

Florea²,

Tonnoir³

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

Objective: This post hoc analysis investigates the effect of vortioxetine on cognitive functioning and depressive symptoms in working adults with major depressive disorder (MDD).Methods: Population data from FOCUS, a double-blind, randomized, placebo-controlled study investigating the efficacy of vortioxetine versus placebo on cognitive functioning and depression in patients with MDD, were used to analyze mean change from baseline scores for the Digit Symbol Substitution Test (DSST), Trail Making Test A/B (TMT-A/B), Stroop, and Perceived Deficits Questionnaire (PDQ). FOCUS, conducted from December 2011 through May 2013, included adult patients with recurrent MDD according to DSM-IV-TR criteria. Change in depression severity (Montgomery-Asberg Depression Rating Scale [MADRS] total score) was analyzed using data from 3 additional short-term placebo-controlled studies (2 of which included duloxetine) and 1 relapse prevention study. Analyses were done according to patients' working status at baseline and workplace position. All analyses were made versus placebo. Results:In FOCUS, the effect versus placebo on the DSST was 5.6 for 10 mg and 5.0 for 20 mg (P < .001 for both doses) in working patients; the effect was 4.0 (P < .001 for both doses) in total study population. The effect remained significant when adjusting for change in MADRS. In patients with "professional" positions, the effect was 9.2 for 10 mg (P = .006) and 9.0 for 20 mg (P = .001). A similar pattern of results was also observed for TMT-A/B, Stroop, PDQ, and MADRS total score. The efficacy of duloxetine was not different in working patients (MADRS). Conclusions:The beneficial effects of vortioxetine on objective and subjective measures of cognitive functioning are greater in working patients with MDD; the observed benefits were independent of improvement in depressive symptoms. 6 Evidence indicates that among adults with MDD, cognitive symptoms account for more variability in workplace performance than does total depressive symptom severity. 7 These observations support research underscoring the notion that cognitive dysfunction is a critical mediator of role impairment in MDD. 8Results from 2 double-blind, randomized, placebo-controlled studies demonstrated a clinical benefit of vortioxetine on cognitive functioning in adults with MDD, including objective neuropsychological tests of executive functioning, speed of processing, verbal learning, and memory.9-11 These studies confirm and extend the results from an earlier double-blind, randomized, placebo-controlled, duloxetine-referenced study with vortioxetine in elderly (≥ 65 years) patients with MDD. 12The beneficial effect observed on measures of cognitive functioning with vortioxetine is of particular importance for individuals with MDD who are working and/or engaged in activities that place high demands on cognition (eg, educational pursuit). Because depression is primarily a disorder affecting people of working age, 13 it is important to understand how the effect of vortioxetine on cognit...

show abstract

Section: Discussionmentioning

confidence: 95%

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

McIntyre¹,

Florea²,

Tonnoir³

et al. 2016

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Evidence for this hypothesis can be found in a study by Lee, Hermens, Porter, and Redoblado-Hodge (2012), who found that factors such as age and education may attenuate Cognitive clusters in MDD and BD 589 the differences in cognitive performance between patients with MDD and control subjects. Approximately one-third of clinical participants were assigned to cluster 2, which showed predominantly preserved cognitive performance, save for selective cognitive impairments.…”

Section: Discussionmentioning

confidence: 99%

Neuropsychological Clustering in Bipolar and Major Depressive Disorder

Cotrena

Branco

Ponsoni

et al. 2017

J Int Neuropsychol Soc

View full text Add to dashboard Cite

Objectives: Cognitive dysfunction is a key feature of major depressive (MDD) and bipolar (BD) disorders. However, rather than a single cognitive profile corresponding to each diagnostic categories, recent studies have identified significant intra-and cross-diagnostic variability in patterns of cognitive impairment. The goal of this study was to contribute to the literature on cognitive heterogeneity in mood disorders by identifying cognitive subprofiles in a population of patients with MDD, BD type I, BD type II, and healthy adults. Methods: Participants completed a neuropsychological battery; scores were converted into Z-scores using normative data and submitted to hierarchical cluster analysis. Results: Three distinct neuropsychological clusters were identified: (1) a large cluster containing mostly control participants, as well as some patients with BD and MDD, who performed at above-average levels on all neuropsychological domains; (2) a cluster containing some patients from all diagnostic groups, as well as healthy controls, who performed worse than cluster 1 on most tasks, and showed impairments in motor inhibition and verbal fluency; (3) a cluster containing mostly patients with mood disorders with severe impairments in verbal inhibition and cognitive flexibility. Conclusions: These findings revealed multiple cognitive profiles within diagnostic categories, as well as significant cross-diagnostic overlap, highlighting the importance of developing more specific treatment approaches which consider patients' demographic and cognitive profiles in addition to their diagnosis. (JINS, 2017, 23, 584-593)

show abstract

“…Cognitive impairment is a common feature of mood disorders, persisting throughout remission or euthymia, 56 and contributing to functional disability (1)(2)(3)(4)(5)(6). Impairment is typically found on tests of attention, working 57 and episodic memory, processing speed and executive function, with standardised effect sizes in the 58 medium range compared to non-mood disordered controls (3)(4)(5)(6).…”

Section: Introduction 54 55mentioning

confidence: 99%

Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants

et al. 2015

View full text Add to dashboard Cite

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.http://eprints.gla.ac.uk/111591/ This study investigated differences in cognitive performance between middle-aged adults with and without a 28 lifetime history of mood disorder features, adjusting for a range of potential confounders. 29 30 Methods 31Cross-sectional analysis of baseline data from the UK Biobank cohort. Adults aged 40-69 (n=143,828) were 32 assessed using measures of reasoning, reaction time and memory. Self-reported data on lifetime features of 33 major depression and bipolar disorder were used to construct groups for comparison against controls. 34Regression models examined the association between mood disorder classification and cognitive 35 performance, adjusting for sociodemographic, lifestyle and clinical confounders.

show abstract

A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder

Cited by 614 publications

References 75 publications

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder

Neuropsychological Clustering in Bipolar and Major Depressive Disorder

Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants

Contact Info

Product

Resources

About